MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2016 International Congress

    Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease

    B. Koentjoro, J.S. Park, C.M. Sue (Sydney, Australia)

    Objective: To identify a new therapeutic target for developing neuroprotective treatment in Parkinson's disease (PD) by improving mitochondrial function through restoration of mitochondrial quality control…
  • 2016 International Congress

    Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype

    I. Huertas Fernandez, S. Jesus, J.A. Lojo, F.J. Garcia Gomez, M. Caceres Redondo, J.M. Oropesa Ruiz, F. Carrillo, L. Vargas Gonzalez, J.F. Martin Rodriguez, P. Gomez Garre, D. Garcia Solis, P. Mir (Sevilla, Spain)

    Objective: To investigate whether Parkinson's disease (PD) motor subtypes differ in their levels of uric acid (UA), and if these differences correlate with the degree…
  • 2016 International Congress

    A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity

    L.V. Kalia, K. Menezes, Y. Zhang, S. Ishikura, N. Tran, H. Chau, A.M. Lozano, S.K. Kalia, J.G. Culotti, S. Suo, W.S. Ryu (Toronto, ON, Canada)

    Objective: To develop a novel transgenic C. elegans model to study dopaminergic neurodegeneration mediated by alpha-synuclein. Background: Targeting alpha-synuclein could be a disease-modifying strategy for…
  • 2016 International Congress

    Sodium butyrate attenuates rotenone-induced neurodegeneration via enhancing autophagy and preventing α-synuclein aggregation

    L. Liu, C. Han, K. Ma, X. Xu, J. Huang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

    Objective: To investigate whether sodium butyrate (NaB) could enhance autophagy and thus exert a neuroprotective effect through the modulation of α-synuclein in animal models of…
  • 2016 International Congress

    Beneficial effect of L-theanine against 3-nitropropionic acid induced neurotoxicity in rats: Possible role of neurotransmitters and nitric oxide

    P. Kumar, S. Jamwal (Moga, India)

    Objective: The present study was intended to investigate the effect of L-theanine against 3-NP induced striatal toxicity. Background: L-theanine is unique amino acid which readily…
  • 2016 International Congress

    Piperine potentiates neuroprotective effect of curcumin in MPTP model of Parkinson’s disease in rats: Impact on neurochemical modulation

    S. Singh, P. Kumar (Moga, India)

    Objective: (1) Curcumin is well tolerated phenolic compound used for CNS disorder but problem is its low oral bioavailability and (2) Piperine is combined to…
  • 2016 International Congress

    Participation in cognitively-stimulating activities and computer use are associated with better cognitive performance in Parkinson’s disease independent from nigrostriatal dopaminergic and cortical cholinergic degenerations

    J.L.B. Bohnen, M.L.T.M. Muller, J.D.J. Haugen, N.I. Bohnen (Ann Arbor, MI, USA)

    Objective: To investigate the relationship between times spent with cognitively stimulating activities and cognitive functions in Parkinson's disease (PD) while accounting for the degree of…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley